We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Design, Synthesis and in Combo Antidiabetic Bioevaluation of Multitarget Phenylpropanoic Acids.
- Authors
Colín-Lozano, Blanca; Estrada-Soto, Samuel; Chávez-Silva, Fabiola; Gutiérrez-Hernández, Abraham; Cerón-Romero, Litzia; Giacoman-Martínez, Abraham; Almanza-Pérez, Julio Cesar; Hernández-Núñez, Emanuel; Wang, Zhilong; Xie, Xin; Cappiello, Mario; Balestri, Francesco; Mura, Umberto; Navarrete-Vazquez, Gabriel
- Abstract
We have synthesized a small series of five 3-[4-arylmethoxy)phenyl]propanoic acids employing an easy and short synthetic pathway. The compounds were tested in vitro against a set of four protein targets identified as key elements in diabetes: G protein-coupled receptor 40 (GPR40), aldose reductase (AKR1B1), peroxisome proliferator-activated receptor gama (PPARγ) and solute carrier family 2 (facilitated glucose transporter), member 4 (GLUT-4). Compound 1 displayed an EC50 value of 0.075 μM against GPR40 and was an AKR1B1 inhibitor, showing IC50 = 7.4 μM. Compounds 2 and 3 act as slightly AKR1B1 inhibitors, potent GPR40 agonists and showed an increase of 2 to 4-times in the mRNA expression of PPARγ, as well as the GLUT-4 levels. Docking studies were conducted in order to explain the polypharmacological mode of action and the interaction binding mode of the most active molecules on these targets, showing several coincidences with co-crystal ligands. Compounds 1–3 were tested in vivo at an explorative 100 mg/kg dose, being 2 and 3 orally actives, reducing glucose levels in a non-insulin-dependent diabetes mice model. Compounds 2 and 3 displayed robust in vitro potency and in vivo efficacy, and could be considered as promising multitarget antidiabetic candidates. This is the first report of a single molecule with these four polypharmacological target action.
- Subjects
PROPIONIC acid; DIABETES; G protein coupled receptors; ALDOSE reductase; PEROXISOME proliferator-activated receptors; SLC45A2 gene; HYPOGLYCEMIC agents
- Publication
Molecules, 2018, Vol 23, Issue 2, p340
- ISSN
1420-3049
- Publication type
Article
- DOI
10.3390/molecules23020340